Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
Return to Top
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest. 2013 Mar; 123(3):1371-81.
View in:
PubMed
subject areas
Animals
Antibodies, Monoclonal
Antineoplastic Agents
CD8-Positive T-Lymphocytes
Cell Line, Tumor
Chemokine CCL2
Down-Regulation
Drug Resistance, Neoplasm
Drug Synergism
Humans
Immunity, Cellular
Immunotherapy
Indoles
Male
Melanoma
Mice
Mice, Inbred C57BL
Molecular Targeted Therapy
Mutation, Missense
Proto-Oncogene Proteins B-raf
Receptors, CCR2
Sulfonamides
T-Lymphocytes, Regulatory
Tumor Necrosis Factor Receptor Superfamily, Member 9
Xenograft Model Antitumor Assays
authors with profiles
Richard Koya